Islet transplantation a decade later and strategies for filling a half-full glass.
Alloislet transplantation for the treatment of type 1 diabetes enjoyed highly favorable status in the first half of the last decade but declined in favor during the second half. In this Perspective, I will briefly review the literature published in this area from 2000 to 2010 for the purposes of extracting lessons we have learned, considering whether the procedure should be deemed a partial success or a partial failure, and offering several strategies to improve alloislet transplantation outcomes in the future. In the end, I hope to strike a positive note about where this procedure is going, and how it will be applied to establish insulin independence in patients with type 1 diabetes.
Robertson
R Paul
RP
Division of Endocrinology and Metabolism, Departments of Medicine and Pharmacology, University of Washington, Seattle, Washington, USA. rpr@pnri.org
D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000601:surgery*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007515:Islets of Langerhans / Q000166:cytology; D016381:Islets of Langerhans Transplantation / Q000379:methods / Q000639:trends*; D008099:Liver / Q000601:surgery; D010180:Pancreatectomy; D012016:Reference Values; D012086:Reoperation / Q000706:statistics & numerical data; D020858:Tissue and Organ Harvesting / Q000379:methods; D017211:Treatment Failure; D016896:Treatment Outcome
D006442:Glycated Hemoglobin